Floatz logo

[203Pb]Pb-MP0712

Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)

Molecular Partners AGPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) cohort.

Asset / SponsorPhaseRating
Abemaciclib
Case Comprehensive Cancer Center
Phase 2B
68Ga-NOTA-AE105
Rigshospitalet, Denmark
Phase 2CCC
Pembrolizumab
Ochsner Health System
Phase 2CCC
[212pb]pb-mp0712
Molecular Partners AG
Phase 1/2CCC
Tarlatamab
University of Arizona
Phase 1/2CC

View all 10 →

Same molecule, other indications

[203Pb]Pb-MP0712 is also rated in:

large cell neuroendocrine carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Gastroenteropancreatic NEC (GEP NEC)Dormant
CCC
Indicative ·
48 / 100
View asset →
urinary bladder small cell neuroendocrine carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →